Upload
martin-susanto
View
216
Download
0
Embed Size (px)
Citation preview
8/13/2019 A COMPARISON OF VANCOMYCIN AND METRONIDAZOLE FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHEA, STRATIFIED BY DISEASE SEVERITY.pptx
1/15
1
Oleh :
Martin Susanto
Gunachitra Devarajoo
Naanthini Dilly Kannan
Pembimbing :
dr. Yuki Yunanda
Departemen KesehatanMasyarakat FK USU
JOURNAL READING
A COMPARISON OF VANCOMYCIN ANDMETRONIDAZOLE FOR THE TREATMENT OF
CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHEA,STRATIFIED BY DISEASE SEVERITY
8/13/2019 A COMPARISON OF VANCOMYCIN AND METRONIDAZOLE FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHEA, STRATIFIED BY DISEASE SEVERITY.pptx
2/15
BACKGROUND
Clostridium difficile associated diarrhea (CDAD) isthe most common infectious etiology of nasocomialdiarrhea in acute care settings. The incidence andseverity of CDAD has been increasing .
Metronidazole is commonly used as first- linetreatment for CDAD but recently there havebeen reports of metronidazole treatmentfailure.
This study is conducted to compare metronidazolewith vancomycin in a prospective, randomized, double-blind, placebo controlled trial to investigate whichmedicine is superior for treating either mild or severeCDAD.
8/13/2019 A COMPARISON OF VANCOMYCIN AND METRONIDAZOLE FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHEA, STRATIFIED BY DISEASE SEVERITY.pptx
3/15
METHOD This study was conducted at Saint Francis Hospital in Chicago.
From October 1994 through June 2002
Patients with CDAD were stratified according to whether theyhad mild or severe disease based on clinical criteria.
INCLUSION EXCLUSION
1. Patients having diarrhea ( 3nonformed stools in 24 hours)
1. Presence of suspected / proven life-
threathening intraabdominal
complications including perforated
viscus / bowel obstruction
2. C.difficile toxin A demonstrated in
the stool within 48 hours after
study entry/ pseudomembranouscolitis found on endoscopic
examination
2. Prior failure of CDAD to respond toeither study drugs
3. Patients have the ability to receiveoral medications
3. Pregnancy and history of allergy to
either study drug during the previous
14 days
8/13/2019 A COMPARISON OF VANCOMYCIN AND METRONIDAZOLE FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHEA, STRATIFIED BY DISEASE SEVERITY.pptx
4/15
8/13/2019 A COMPARISON OF VANCOMYCIN AND METRONIDAZOLE FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHEA, STRATIFIED BY DISEASE SEVERITY.pptx
5/15
RESULTS
One hundred seventy-two patients were enrolled, and 150 ofthese patients successfully completed the trial.
The overall rate of cure was 84% (66 of 79 patients) in themetronidazole group and 97% (69 of 71 patients) in thevancomycin group (P = .006)
Among the patients with mild CDAD, treatment withmetronidazole or vancomycin resulted in clinical cure in 90% and98% of the patients, respectively (P = .36).
Among the patients with severe CDAD, treatment withmetronidazole or vancomycin resulted in clinical cure in 76% and
97% of the patients, respectively (P = .02). Clinical symptoms recurred in 14% of the patients treated with
metronidazole and 7% of those treated with vancomycin.
8/13/2019 A COMPARISON OF VANCOMYCIN AND METRONIDAZOLE FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHEA, STRATIFIED BY DISEASE SEVERITY.pptx
6/15
DISEASESEVERITY
NO. OF PATIENTS CURED/ NO. OF PATIENTSTREATED (%)
MTZ GROUP VM GROUP TOTAL P VALUE
MILD 37 / 41 (90) 39 / 40 (98) 76 / 81 (94) .36
SEVERE 29 / 38 (76) 30 / 31 (97) 59 / 69 (86) .02
ALL 66 / 79 (84) 69 / 71 (97) 135 / 150 (90) .006
Rate of Cure of Clostridium DifficileAssociatedDiarrhea by Disease Severity and Treatment
8/13/2019 A COMPARISON OF VANCOMYCIN AND METRONIDAZOLE FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHEA, STRATIFIED BY DISEASE SEVERITY.pptx
7/15
THERAPY WORKSHEET
Was the assignment of patients totreatments randomized?
Yes. The patients were randomly assignedto receive oral Metronidazole or oralVancomycin for 10 days[ pg 1; Abstract or pg 2; study design]
Was the randomization list concealed? Yes. A member of the pharmacy staffrandomized participants by selecting acard from a sealed envelope that had 1 ofthe active study drugs listed on it.[ pg 2; Treatment regimen]
Was follow-up of patients sufficientlylong and complete?
Yes. The study were conducted fromOctober 1994 through June 2002. From172 patients, 150 patients successfullycompleted the trial ( loss to follow up 20%) [ pg 1; methods and pg 3; Results]
Are the results of this single preventive or therapeutictrial valid?
8/13/2019 A COMPARISON OF VANCOMYCIN AND METRONIDAZOLE FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHEA, STRATIFIED BY DISEASE SEVERITY.pptx
8/15
Were all patients analyzed in the groupsto which they were randomized?
Yes. The patients were randomized intometronidazole group and vancomycingroup and both groups were analyzed intomild and severe disease groups based on
severity assessment score developed forthis study.[ pg 2; Study design]
Were patients, clinicians, and studypersonnel kept blind to treatment?
Yes. This study is double-blind[ pg 2; Study design]
Were the groups treated equally, apartfrom the experimental treatment?
Yes. Patients frm both groups weremonitored daily to determine thefrequency of stools and the first day onwhich the diarrhea resolved, daily vitalsigns and abdominal symptoms wererecorded. [ pg 2 ; Study design ]
Were the groups similar at the start ofthe trial apart from the experimentaltherapy?
Yes. Both groups consist of patients whohad stool assay performed for C.difficiletoxin.[ pg 1 ; Methods ]
8/13/2019 A COMPARISON OF VANCOMYCIN AND METRONIDAZOLE FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHEA, STRATIFIED BY DISEASE SEVERITY.pptx
9/15
Are the valid results of this randomized trialimportant?
What is the magnitude of thetreatment effect?
NNT, ARR, RRR, CER, EER
How precise is the estimate of thetreatment effect?
P value < 0.05 ( P value = 0.006 ), thetreatment effect is precise
YES( CURED)
NO( DIDNT CURE)
TOTAL
CONTROL( METRONIDAZOL )
66 13 79
EXPERIMENT( VANCOMYCIN )
69 2 71
8/13/2019 A COMPARISON OF VANCOMYCIN AND METRONIDAZOLE FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHEA, STRATIFIED BY DISEASE SEVERITY.pptx
10/15
CALCULATIONS
Relative risk
reduction
(RRR)
Absolute risk
reduction
(ARR)
Number
needed
to treat
(NNT)
CER
= 66 / 79
= 0,84
= 84 %
EER
= 69 / 71
= 0,97
= 97 %
CER EERCER
= 0,840,97
0,84
= - 0,15
= -15 %
CER EER
= 0,840,97
= - 0,13
1/ARR
= 1 / 0,13
= 7,69
= 7
95% CI a -0,22 to -0,04 4 to 25
8/13/2019 A COMPARISON OF VANCOMYCIN AND METRONIDAZOLE FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHEA, STRATIFIED BY DISEASE SEVERITY.pptx
11/15
Can you apply this valid, important evidence abouttherapy in caring for your patient?
Do these results apply to ourpatient?
Yes. Because CDAD is common inIndonesia
Is our patient so different from
those in the study that itsresults cannot apply?
No. Because the characteristics
of the patients in the study andthe patients in our country aresimilar, so the result can beapplied here.
Is the treatment feasible in our
setting?
Yes. Because both Metronidazole
and Vancomycin are available inIndonesia.
8/13/2019 A COMPARISON OF VANCOMYCIN AND METRONIDAZOLE FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHEA, STRATIFIED BY DISEASE SEVERITY.pptx
12/15
What are our patients potential benefits and harmsfrom the therapy?
Risk of the outcome in our patient,relative to patients in the trial.
Expressed as a decimal:
NNT/ f = 7,69 / 1 = 7,69
(NNT for patients like ours)
Our patients expected event rateif they received
the control treatment (PEER) =______
1/(PEER RRR) = 1/________=______
(NNT for patients like ours)
Method I : f
Method II :1/(PEER RRR)
8/13/2019 A COMPARISON OF VANCOMYCIN AND METRONIDAZOLE FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHEA, STRATIFIED BY DISEASE SEVERITY.pptx
13/15
Are our patients values and preferences satisfied bythe regimen and its consequences?
Do we and our patient have aclear assessment of their values
and preferences?
-
Are they met by this regimenand its consequences?
-
8/13/2019 A COMPARISON OF VANCOMYCIN AND METRONIDAZOLE FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHEA, STRATIFIED BY DISEASE SEVERITY.pptx
14/15
CONCLUSIONS
This study have shown that metronidazole and vancomycin areequally effective for the treatment of mild CDAD, butvancomycin is superior for treating patients with severe CDAD.
This may require a modification of treatment guidelines for
CDAD, especially because of the increasing prevalence of anepidemic strain that is producing more-severe disease.
8/13/2019 A COMPARISON OF VANCOMYCIN AND METRONIDAZOLE FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHEA, STRATIFIED BY DISEASE SEVERITY.pptx
15/15
TERIMA KASIH